Drug Profile
Satavaptan
Alternative Names: Aquilda; SR 121463B; SR-121463Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antihypertensives; Heart failure therapies; Morpholines; Small molecules; Spiro compounds
- Mechanism of Action Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Heart failure; Hypertension; Hyponatraemia; Liver cirrhosis; Nephrotic syndrome
Most Recent Events
- 26 Apr 2009 Adverse events data from a trial in liver cirrhosis presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
- 31 Dec 2008 Discontinued - Phase-III for Cirrhosis in Argentina (PO)
- 31 Dec 2008 Discontinued - Phase-III for Cirrhosis in Australia (PO)